Superoxide dismutase liposomal - Apeiron Biologics/Polymun Scientific

Drug Profile

Superoxide dismutase liposomal - Apeiron Biologics/Polymun Scientific

Alternative Names: APN-201; Liposomal recombinant human Cu/Zn-superoxide dismutase; Lipoxysan; rhSOD - Apeiron Biologics/Polymun Scientific

Latest Information Update: 27 Jul 2015

Price : $50

At a glance

  • Originator Polymun Scientific
  • Developer Apeiron Biologics; Polymun Scientific
  • Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Oxidoreductases
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Peyronie's disease
  • No development reported Radiodermatitis

Most Recent Events

  • 27 Jul 2015 No recent reports on development identified - Phase-II for Radiodermatitis (Prevention) in Austria (Topical)
  • 12 Mar 2013 Efficacy and adverse events data from a phase I/II trial in Radiodermatitis (Prevention) released by Apeiron Biologics
  • 23 Jan 2012 Apeiron Biologics initiates enrolment in a phase Ib/II trial for Radiodermatitis (Prevention) in Austria (NCT01513278)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top